Journal of Headache and Pain最新文献

{"title":"Correction: Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU‑005 reduces ex vivo cortical spreading depression.","authors":"Flavia Brugia, Konstantin Ivanov, Auni Aroviita, Raisa Giniatullina, Marko Lehtonen, Tarja Malm, Juha Savinainen, Rashid Giniatullin, Adriana Della Pietra","doi":"10.1186/s10194-025-02053-9","DOIUrl":"https://doi.org/10.1186/s10194-025-02053-9","url":null,"abstract":"","PeriodicalId":16013,"journal":{"name":"Journal of Headache and Pain","volume":"26 1","pages":"111"},"PeriodicalIF":7.3,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered aminoacid and lipid metabolism in a rat orofacial inflammation model determined by omics approach: potential role in trigeminal sensitisation.","authors":"Krisztina Takács-Lovász, Timea Aczél, Violetta Mohos, Máté Harmath, Jennet Pirkuliyeva, Gellért Karvaly, Róbert Farkas, Michal Ciborowski, Joanna Godzien, Kata Bölcskei, József Kun, Zsuzsanna Helyes","doi":"10.1186/s10194-025-02024-0","DOIUrl":"https://doi.org/10.1186/s10194-025-02024-0","url":null,"abstract":"<p><strong>Background: </strong>Trigeminal activation and sensitisation involved in chronic inflammatory orofacial pain share several similarities with headaches, including migraine. Therefore, understanding the pathophysiological mechanisms is important to determine novel therapies, in which animal models are crucial. Here we aimed to identify key mediators, mechanisms and networks using unbiased multi-omic approaches in a rat orofacial inflammatory pain model.</p><p><strong>Methods: </strong>Complete Freund's Adjuvant (CFA, 50 µl, 1 mg/mL) was injected into the right whisker pad of male Wistar rats (n = 5-11/group), mechanonociceptive threshold was measured by von Frey filaments. Plasma concentrations of metabolites were measured both by targeted (MxP Quant 500 kit) and untargeted mass spectrometry methods on day 3 when maximal facial allodynia developed. Next-generation sequencing of the trigeminal ganglia (TG) was performed, furthermore, transcriptomic and plasma metabolomic data were analysed together.</p><p><strong>Results: </strong>Plasma carnosine, serotonin and fatty acid levels significantly increased, while tryptophan, kynurenine, tyrosine, phenylalanine, asparagine, glycerolipids, and sphingolipids decreased in response to orofacial inflammation. CFA upregulated the Cxcr3 chemokine receptor and downregulated GNRHR in the TG. Bioinformatic analysis revealed altered amino acid metabolism and fatty acid beta-oxidation involved in mitochondrial energy production, neuroinflammation and immune responses.</p><p><strong>Conclusions: </strong>Integrated joint pathway analysis of metabolomic and transcriptomic data provides a useful approach to determine pathophysiological mechanisms of trigeminal sensitization and identify novel drug targets for orofacial pain and headaches.</p>","PeriodicalId":16013,"journal":{"name":"Journal of Headache and Pain","volume":"26 1","pages":"108"},"PeriodicalIF":7.3,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12063288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Headache-attributed burden and a health-care needs assessment in Delhi and National Capital Region of India: estimates from a cross-sectional population-based study.","authors":"Anand Krishnan, Debashish Chowdhury, Ashish Duggal, Ritvik Amarchand, Andreas Husøy, Timothy J Steiner","doi":"10.1186/s10194-025-02036-w","DOIUrl":"https://doi.org/10.1186/s10194-025-02036-w","url":null,"abstract":"<p><strong>Background: </strong>We have previously shown headache to be highly prevalent in Delhi and National Capital Region of northern India, as we did earlier in Karnataka State in the south. Here we present a complementary study performed contemporaneously of headache-attributed burden, along with a population health-care needs assessment.</p><p><strong>Methods: </strong>In a cross-sectional study using the standardised methodology of the Global Campaign against Headache, we randomly selected households, and one member aged 18-65 years from each, making unannounced visits. Trained interviewers used the HARDSHIP questionnaire incorporating enquiry into various aspects of headache-attributed burden: symptom burden, lost health, impaired participation in daily activities, quality of life (QoL) and willingness to pay (WTP) for treatment. Enquiry included questions about headache yesterday (HY).</p><p><strong>Results: </strong>Of N = 2,066, participants reporting headache in the past year spent 9.5% of their time with headache of moderate intensity (1.8 on the scale of 1-3). Population-level estimates of all time spent with headache were in the range 5.5-6.6%. On this measure, migraine (8.2%) was, at individual level, much more burdensome than tension-type headache (TTH) (1.7%), and females with migraine or TTH were more burdened (8.7% and 2.0% respectively) than males (6.0% and 1.0%). Migraine accounted for substantial health loss (3.6%) at individual level (disability weights from the Global Burden of Disease study factored in), but both measures of overall burden (QoL and WTP) found it greatest among those with probable medication-overuse headache (pMOH) or other causes of headache on ≥ 15 days/month (H15+), with TTH least. For all headache types, participation was more impaired in household than in paid work, the latter being little affected (overall, males 0.3 lost days/month, females 0.1). Impaired participation in social or leisure activities was close to unmeasurably low. Impaired participation from HY was 1.8% across all domains of activity. One quarter (26%) of the population aged 18-65 years would be expected to benefit from health care, meeting our criteria for need: 16.1% with migraine, 6.4% with H15+.</p><p><strong>Conclusion: </strong>Headache disorders in northern India are not only prevalent but also associated with high burden. One quarter of the adult population would benefit from professional headache care.</p>","PeriodicalId":16013,"journal":{"name":"Journal of Headache and Pain","volume":"26 1","pages":"106"},"PeriodicalIF":7.3,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world use of over-the-counter medications by patients with migraine in Japan: results from the OVERCOME (Japan) 2nd study.","authors":"Ryotaro Ishii, Tsubasa Takizawa, Shiho Suzuki, Daisuke Danno, Moemi Miura, Yoshinori Tanizawa, Satoshi Osaga, Chie Hashimoto, Mika Komori","doi":"10.1186/s10194-025-02046-8","DOIUrl":"10.1186/s10194-025-02046-8","url":null,"abstract":"<p><strong>Background: </strong>People with migraine may prefer over-the-counter (OTC) drugs because of multiple reasons, but their overuse can cause medication overuse headaches. This analysis of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) 2nd study describes the real-world use of OTC headache drugs and the challenges that potentially prevent people with migraine from accessing appropriate medical management in Japan.</p><p><strong>Methods: </strong>This analysis of the cross-sectional, population-based, nationwide online survey included adults with migraine. Respondents reported their experiences with prescription and OTC drugs for migraine, migraine-specific drug awareness, and attitude towards migraine. Subgroup analyses were performed based on the number of monthly headache days (MHD) and the frequency of OTC drug use/month.</p><p><strong>Results: </strong>The 19,590 respondents with migraine (68.8% female; mean [SD] age 40.5 [13.1] years) had mean (SD) 3.5 (5.2) MHDs; 29.0% consulted doctors in the past year for migraine. OTC drug use in the past year was common (≥ 62.1%) regardless of doctor consultation or number of MHDs. Among respondents who answered that they would usually use prescribed drugs when they have a migraine attack, 35.2% reported that they would typically use OTC drugs too. The frequency of OTC drug use was the same or higher than that of prescribed drugs in 51.3% of the respondents who consulted doctors in the past year. Only 14.6% of respondents discussed OTC drugs with doctors during consultations in the past year. Migraine-specific drug access and awareness were limited even among frequent OTC drug users (≥ 10 days/month); 18.2% used triptans, but 65.5% never heard of it. Among 37.1% of respondents who had hesitated to visit a doctor, 'I could handle it myself with OTC medicine' was the most common reason for hesitation (34.9%).</p><p><strong>Conclusion: </strong>OTC drug use is common among people with migraine; however, it is not frequently discussed with doctors. Many respondents, even those with frequent OTC drug use, did not have access or awareness of migraine-specific drugs. To prevent medication overuse for migraine, the use of OTC drugs should also be discussed and managed.</p>","PeriodicalId":16013,"journal":{"name":"Journal of Headache and Pain","volume":"26 1","pages":"107"},"PeriodicalIF":7.3,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmasking the relationship between CGRP and glutamate: from peripheral excitation to central sensitization in migraine.","authors":"Fahimeh Martami, Kathleen F Holton","doi":"10.1186/s10194-025-02043-x","DOIUrl":"https://doi.org/10.1186/s10194-025-02043-x","url":null,"abstract":"<p><p>The exact mechanisms that trigger the activation of the trigeminovascular system in migraine remain unclear. The involvement of calcitonin gene-related peptide (CGRP) in migraine is well-documented, and treatments aimed at blocking CGRP activity have proven successful in reducing migraine attacks for some patients. However, around one third of individuals do not respond to these therapies, which are also limited by factors like cost, side effects, and contraindications. There is growing evidence suggesting that glutamate, an excitatory neurotransmitter, plays a crucial role in the onset and maintenance of migraine pain, partially by enhancing CGRP release. Increased glutamate levels have been linked to both peripheral and central sensitization, potentially contributing to the development and persistence of chronic migraine. The relationship between CGRP and glutamate is complex, with glutamate possibly acting as an upstream trigger for CGRP release. This review examines the interplay between CGRP and glutamate, and their involvement in both peripheral and central sensitization. It also explores the therapeutic potential of targeting either glutamate or CGRP, aiming to address both peripheral and central migraine mechanisms. Finally, the role of triggers in migraine initiation at the peripheral level is discussed, offering insights into potential preventive strategies.</p>","PeriodicalId":16013,"journal":{"name":"Journal of Headache and Pain","volume":"26 1","pages":"101"},"PeriodicalIF":7.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, efficacy, and compliance of moderate-to-high dose eptinezumab and erenumab in chronic migraine patients with medication-overuse headache: an updated systematic review and meta-analysis.","authors":"Nhan Nguyen, Vinh Ho Quang Tri, Vy Nguyen Ngoc Dan, Nghi Bao Tran, Laszlo Olah, Mate Heja","doi":"10.1186/s10194-025-02047-7","DOIUrl":"10.1186/s10194-025-02047-7","url":null,"abstract":"<p><strong>Background: </strong>The use of monoclonal antibodies targeting Calcitonin Gene-Related Peptide (CGRP) is an established treatment for chronic migraine (CM). However, its efficacy in CM patients with medication overuse headache (MOH) remains underexplored, and data on the safety and patient compliance of standard-to-high doses, especially Eptinezumab and Erenumab, over at least three months are limited.</p><p><strong>Objective: </strong>This study aims to evaluate the efficacy and safety of anti-CGRP therapy (Eptinezumab and Erenumab) in CM and MOH patients. Specifically, it assesses changes in monthly migraine days (MMDs) after 12 weeks, risk of treatment-emergent adverse events (TEAEs) leading to discontinuation, serious TEAEs, common adverse effects, and MOH remission at 6 months.</p><p><strong>Methods: </strong>A systematic search of PubMed, Cochrane, and Scopus databases identified randomized controlled trials (RCTs) evaluating standard or high dose anti-CGRP therapy in CM patients strictly with MOH. Studies included were required to report a ≥ 50% reduction in MMDs after ≥ 12 weeks, serious TEAEs, TEAEs leading to discontinuation, common adverse events, and MOH remission at 6 months. Heterogeneity was assessed using I² statistics and a random-effects model.</p><p><strong>Results: </strong>Three RCTs with 769 patients receiving standard-to-high dose anti-CGRP monoclonal antibodies (Eptinezumab and Erenumab) for ≥ 12 weeks were included. Anti-CGRP therapy significantly increased the likelihood of a ≥ 50% reduction in MMDs compared to placebo (OR: 2.43; 95% CI: 1.68-3.51; p < 0.00001). No substantial differences were found in TEAEs leading to discontinuation, nasopharyngitis, upper respiratory tract infections, or serious TEAEs between the anti-CGRP and placebo groups. The likelihood of MOH remission was approximately double in the anti-CGRP group (OR: 1.97; 95% CI: 1.40-2.78; p = 0.0001).</p><p><strong>Conclusion: </strong>Standard-to-high dose anti-CGRP therapies (eptinezumab, erenumab) effectively reduce monthly migraine days and improve MOH remission rates with minimal adverse effects, showing good tolerability in CM patients with MOH.</p>","PeriodicalId":16013,"journal":{"name":"Journal of Headache and Pain","volume":"26 1","pages":"99"},"PeriodicalIF":7.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of monoclonal antibodies against CGRP in migraine patients with fibromyalgia comorbidity: a retrospective monocentric observational study.","authors":"Marina de Tommaso, Stefania Scannicchio, Giulia Paparella, Livio Clemente, Giuseppe Libro","doi":"10.1186/s10194-025-02034-y","DOIUrl":"https://doi.org/10.1186/s10194-025-02034-y","url":null,"abstract":"<p><strong>Background: </strong>Migraine is a common comorbidity with fibromyalgia (FM). CGRP is a potent inflammatory neuropeptide that may play a role in somatic and visceral pain either inflammatory or neuropathic. Previous studies have reported a significant number of migraine patients with FM responding to anti-CGRP therapies. The potential impact on diffuse pain and global disability associated with fibromyalgia is still unclear. In this retrospective, observational, cross-sectional study, we aimed to analyze the effects of a monoclonal antibody therapy in a subpopulation of migraineurs with FM compared to patients without this comorbidity by assessing the headache frequency and disability as well as the severity of FM (assessed by the Fibromyalgia Impact Questionnaire (FIQ).</p><p><strong>Methods: </strong>Among 1088 patients came for the first visit to our headache Center between January 1, 2021, and December 31, 2022, we examined six-month outcomes of 148 migraine patients prescribed various monoclonal antibodies to CGRP, erenumab, galcanezumab, and fremanezumab. One hundred and twenty-two patients were selected, 26 of whom suffered from FM. We retrospectively evaluated the following characteristics at baseline (T0) and after 6 months (T1),headache frequency and severity, number of days with symptomatic medication, and MIDAS score. In the FM patients, we evaluated the FIQ and the intensity of somatic pain using a numerical rating scale from 0 to 10.</p><p><strong>Results: </strong>Headache characteristics improved similarly in patients with and without FM comorbidity. The number of patients in whom headache frequency decreased by at least 50% was similar in the two migraine groups. In patients with FM, both fibromyalgia-related disability and somatic pain improved. The improvement in fibromyalgia disability was significantly correlated with the improvement in migraine-related disability.</p><p><strong>Conclusions: </strong>We found that in migraine suffereres with FM, anti-CGRP monoclonal antibodies had a similar beneficial effect on migraine as in non-fibromyalgia patients, in addition to reducing somatic pain and global disability from the disease. The anti-CGRP agents, represent a good option for the treatment of migraineurs with fibromyalgia, for which no resolutive therapy is yet available.</p>","PeriodicalId":16013,"journal":{"name":"Journal of Headache and Pain","volume":"26 1","pages":"102"},"PeriodicalIF":7.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of community pharmacists in managing common headache disorders, and their integration within structured headache services: position statement on behalf of the European Headache Federation (EHF) and Lifting The Burden (LTB: the Global Campaign against Headache), with the formal endorsement of the International Pharmaceutical Federation.","authors":"Heba BaniHani, Christian Lampl, Antoinette MaassenvandenBrink, Faisal Mohammad Amin, Louise Ninett Carlsen, Gianluca Coppola, Christina Deligianni, Raquel Gil-Gouveia, Philip R Holland, Andreas K Husøy, Rigmor Jensen, Madalena Plácido, Uwe Reuter, Kristina Ryliškienė, Margarita Sanchez Del Río, Henrik Winther Schytz, Erling Tronvik, Jan Versijpt, Timothy J Steiner","doi":"10.1186/s10194-025-02021-3","DOIUrl":"10.1186/s10194-025-02021-3","url":null,"abstract":"<p><p>In the sustainable development goals (SDG) context of seeking universal health coverage, the expanding gap between the supply of specialized and primary health-care providers of headache-related health care and the care needs of the very large number of people affected by headache is a formidable but not insoluble public-health challenge. Structured headache services provide a cost-effective framework wherein controlled patient flows enable the care needs of people with headache to be met at appropriate levels, but these services may still be overwhelmed by inappropriate demand.Community pharmacists are an underutilized resource, potentially well able to provide the solution. To do so, they must, as a profession, be integrated into structured headache services.What remains to be determined is how to achieve this integration in an encouraging climate for change, which recognises the potential for relieving strained health-care systems and meeting a range of health-care needs by expanding pharmacists' scope of practice.This position statement on behalf of the European Headache Federation (EHF) and Lifting The Burden (LTB) is formally endorsed by the International Pharmaceutical Federation (FIP).</p>","PeriodicalId":16013,"journal":{"name":"Journal of Headache and Pain","volume":"26 1","pages":"100"},"PeriodicalIF":7.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lateral habenula-rostromedial tegmental nucleus circuit mediates inflammatory pain in mice.","authors":"Yanfei Sun, Jing Cao, Chunpeng Xu, Jiangtao Sun, Xiaofeng Liu, Zhenguang Shi, SiMeng An, Danyang Zhao, Dongjie Sun, Xuxin Wang, Guoyan Zhao, Chi Zhang, Guangjian Li, Jinyu Xiao, Jing Yang, Hua Zhao","doi":"10.1186/s10194-025-02052-w","DOIUrl":"https://doi.org/10.1186/s10194-025-02052-w","url":null,"abstract":"<p><strong>Background: </strong>The monoamine system, particularly the serotonergic neurons in the dorsal raphe nucleus (DRN), associated with the synthesis and release of 5-hydroxytryptamine, is crucial for regulating pain. The lateral habenula (LHb) modulates DRN neurons by acting through GABAergic neurons located in the rostromedial tegmental nucleus (RMTg). However, the role of RMTg in mediating the LHb and regulating pain remains unclear. Thus, we aimed to assess the role of the LHb-RMTg pathway in inflammatory pain.</p><p><strong>Methods: </strong>Male C57BL/6 mice were used in the chemogenetic experiments, while male and female Vglut2-ires-cre mice were used in the optogenetic experiments; in both experiments, inflammatory pain model and control groups were established. We performed the Hargreaves and Von Frey tests to assess nociceptive behavior as well as immunohistochemistry staining after chemogenetic activation experiments. Statistical analyses were performed using a t-test, one-way analysis of variance (normally distributed data) or Kruskal-Wallis test (non-normally distributed data) and two-way analysis of variance.</p><p><strong>Results: </strong>Chemogenetic activation/inhibition of RMTg-projecting LHb excitatory neurons was sufficient to decrease or increase heat sensitivity thresholds. Additionally, inhibition of the LHb-RMTg circuit reversed the decreased heat sensitivity thresholds under inflammatory pain conditions using chemogenetic and optogenetic approaches. However, this circuit did not affect mechanical allodynia thresholds, and chemogenetic activation of the circuit decreased c-Fos immunoreactivity in the DRN.</p><p><strong>Conclusions: </strong>Our results indicate that activating glutamatergic neurons within the LHb heightens pain sensitivity by triggering GABAergic neurons in the RMTg, which in turn influences neuronal activity in the DRN. This research offers fresh perspectives on the pain mechanism, potentially revealing new therapeutic avenues for managing inflammatory pain.</p>","PeriodicalId":16013,"journal":{"name":"Journal of Headache and Pain","volume":"26 1","pages":"105"},"PeriodicalIF":7.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden of migraine and predictions in the Asia-Pacific region, 1990-2021: a comparative analysis of China, South Korea, Japan, and Australia.","authors":"Yun-Xia Wang, Guang-Shuang Lu, Jin-Jing Zhao, Wei Dai, Na Zheng, Guo-En Yao, Ruo-Zhuo Liu","doi":"10.1186/s10194-025-02048-6","DOIUrl":"https://doi.org/10.1186/s10194-025-02048-6","url":null,"abstract":"<p><strong>Background: </strong>Migraine is a leading cause of disability worldwide, significantly impacting quality of life and healthcare systems. Despite its high prevalence and burden, migraine remains underprioritized in global health policies. This study examines the epidemiological trends of migraine in Australia, China, Japan, and South Korea from 1990 to 2021, highlighting regional disparities and forecasting future burdens.</p><p><strong>Methods: </strong>This study utilized data from the Global Burden of Disease (GBD) 2021 to analyze incidence, prevalence, and years lived with disability (YLDs) of migraine. Age-standardized rates (ASRs) were calculated to enable fair cross-country comparisons. Joinpoint regression analysis was applied to assess temporal trends, while Bayesian age-period-cohort (BAPC) modeling was used to project future trends until 2050. Additionally, decomposition analysis was conducted to differentiate the effects of population aging, growth, and epidemiological changes.</p><p><strong>Results: </strong>In 2021, China had the highest migraine burden, with 13.05 million new cases and 184.75 million prevalent cases, followed by Australia, Japan, and South Korea. Incidence rates peaked in adolescence (10-14 years), while prevalence and disability were highest in middle-aged women (40-44 years). From 1990 to 2021, Australia exhibited stable trends, China experienced increasing burden, Japan saw a decline due to aging, and Korea exhibited mixed patterns influenced by opposing demographic and epidemiological forces. Future projections suggest a stable trend in Australia, declining incidence in China and Japan, and continued burden in Korea.</p><p><strong>Conclusion: </strong>Migraine remains a significant public health challenge across all four countries, with age, gender, and demographic changes playing key roles in burden variations. The study highlights the need for region-specific healthcare strategies and age- and gender-sensitive interventions. Future research should explore socioeconomic, behavioral, and healthcare access factors to refine migraine management strategies.</p>","PeriodicalId":16013,"journal":{"name":"Journal of Headache and Pain","volume":"26 1","pages":"104"},"PeriodicalIF":7.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144020929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}